Cáncer de próstata metastásico hormono-sensible: ¿Cómo deberíamos tratar a nuestros pacientes?

Hormone-sensitive metastatic prostate cancer: How should we treat our patients?

Contenido principal del artículo

Ray Manneh Kopp

Detalles del artículo

Biografía del autor/a (VER)

Ray Manneh Kopp, Sociedad de Oncología y Hematología del Cesar, Valledupar - Colombia

Ray Manneh Kopp, MD

Oncología Clínica. Oncología Genitourinaria.

Sociedad de Oncología y Hematología del Cesar.

Grupo de Oncología Genitourinaria de Colombia (GOGUC).   

Referencias (VER)

Francini E, Gray K, Xie W. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate Sep;78 (12):889-895. https://doi.org/10.1002/pros.23645

Gravis G, Boher J-M, Chen Y-H. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG_AFU15 studies. Eur Urol Jun;73 (6):847-855. https://dx.doi.org/10.1016%2Fj.eururo.2018.02.001

Sweeney C, Chen Y-H, Carducci M. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373:737-746. https://doi.org/10.1200/jco.2017.75.3657

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet.2016 Mar 19;387 (10024): 1163-77. https://doi.org/10.1016/s0140-6736(15)01037

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al. Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 2017. Jul 27;377(4):352-360. https://doi.org/10.1056/nejmoa1704174

James N, de Bono J, Spears M. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017 Jul 27;377(4):338-35. https://goi.org/10.1056/NEJMoa1702900

Parker C, James N, Brawley C. Clarke N, Hoyle A, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018 Dec 1;392 (10162):2353-2366. https://doi.org/10.1016/s0140-6736(18)32486-3

Amstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide of placebo in men with metastatic hormonse-sensitive prostate cancer. J Cllin Oncol. 2019 Nov 10;37(32): 2974-2986. https://doi.org/10.1200/jco.19.00799

Davis I, Martin A, Stockler M, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019 Jul 11;381(2);121-131. https://doi.org/10.1056/nejmoa1903835

Chi K, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019 Jul 4;381(1):13-24. https://doi.org/10.1056/nejmoa1903307